Your browser doesn't support javascript.
loading
Remission of type 2 diabetes after gastrectomy for gastric cancer: diabetes prediction score.
Kwon, Yeongkeun; Kwon, Jin-Won; Ha, Jane; Kim, Dohyang; Cho, Jaehyeong; Jeon, Soo Min; Park, Shin-Hoo; Hwang, Jinseub; Kim, Nam Hoon; Park, Sungsoo.
Afiliação
  • Kwon Y; Division of Foregut Surgery, Korea University College of Medicine, Seoul, Korea.
  • Kwon JW; Centre for Obesity and Metabolic Diseases, Korea University Anam Hospital, Seoul, Korea.
  • Ha J; BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea.
  • Kim D; Centre for Obesity and Metabolic Diseases, Korea University Anam Hospital, Seoul, Korea.
  • Cho J; Department of Medicine, Korea University College of Medicine, Seoul, Korea.
  • Jeon SM; Department of Statistics, Daegu University, Gyeongbuk, Korea.
  • Park SH; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.
  • Hwang J; BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea.
  • Kim NH; Division of Foregut Surgery, Korea University College of Medicine, Seoul, Korea.
  • Park S; Centre for Obesity and Metabolic Diseases, Korea University Anam Hospital, Seoul, Korea.
Gastric Cancer ; 25(1): 265-274, 2022 01.
Article em En | MEDLINE | ID: mdl-34296379
BACKGROUND: Although type 2 diabetes (T2D) remission after gastric cancer surgery has been reported, little is known about the predictors of postoperative T2D remission. METHODS: This study used data from a nationwide cohort provided by the National Health Insurance Service in Korea. We developed a diabetes prediction (DP) score, which predicted postoperative T2D remissions using a logistic regression model based on preoperative variables. We applied machine-learning algorithms [random forest, XGboost, and least absolute shrinkage and selection operator (LASSO) regression] and compared their predictive performances with those of the DP score. RESULTS: The DP score comprised five parameters: baseline body mass index (< 25 or ≥ 25 kg/m2), surgical procedures (subtotal or total gastrectomy), age (< 65 or ≥ 65 years), fasting plasma glucose levels (≤ 130 or > 130 mg/dL), and antidiabetic medications (combination therapy including sulfonylureas, combination therapy not including sulfonylureas, single sulfonylurea, or single non-sulfonylurea]). The DP score showed a clinically useful predictive performance for T2D remission at 3 years after surgery [training cohort: area under the receiver operating characteristics (AUROC) 0.73, 95% confidence interval (CI), 0.71-0.75; validation cohort: AUROC 0.72, 95% CI 0.69-0.75], which was comparable to that of the machine-learning models (random forest: AUROC 0.71, 95% CI 0.68-0.74; XGboost: AUROC 0.70, 95% CI 0.67-0.73; LASSO regression: AUROC 0.75, 95% CI 0.73-0.78 in the validation cohort). It also predicted the T2D remission at 6 and 9 years after surgery. CONCLUSIONS: The DP score is a useful scoring system for predicting T2D remission after gastric cancer surgery.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Diabetes Mellitus Tipo 2 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Diabetes Mellitus Tipo 2 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article